These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 21044307)

  • 1. Long-term mortality in HIV patients virally suppressed for more than three years with incomplete CD4 recovery: a cohort study.
    Engsig FN; Gerstoft J; Kronborg G; Larsen CS; Pedersen G; Røge B; Jensen J; Nielsen LN; Obel N
    BMC Infect Dis; 2010 Nov; 10():318. PubMed ID: 21044307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The predictive role of CD4
    Li CX; Li YY; He LP; Kou J; Bai JS; Liu J; Tian B; Cao LJ; Wang KH; Kuang YQ
    BMC Immunol; 2019 Aug; 20(1):31. PubMed ID: 31455209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery.
    Engsig FN; Zangerle R; Katsarou O; Dabis F; Reiss P; Gill J; Porter K; Sabin C; Riordan A; Fätkenheuer G; Gutiérrez F; Raffi F; Kirk O; Mary-Krause M; Stephan C; de Olalla PG; Guest J; Samji H; Castagna A; d'Arminio Monforte A; Skaletz-Rorowski A; Ramos J; Lapadula G; Mussini C; Force L; Meyer L; Lampe F; Boufassa F; Bucher HC; De Wit S; Burkholder GA; Teira R; Justice AC; Sterling TR; M Crane H; Gerstoft J; Grarup J; May M; Chêne G; Ingle SM; Sterne J; Obel N;
    Clin Infect Dis; 2014 May; 58(9):1312-21. PubMed ID: 24457342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Factors Related to CD4+ T-Cell Recovery and Viral Suppression in Patients Who Have Low CD4+ T Cell Counts at the Initiation of HAART: A Retrospective Study of the National HIV Treatment Sub-Database of Zhejiang Province, China, 2014.
    He L; Pan X; Dou Z; Huang P; Zhou X; Peng Z; Zheng J; Zhang J; Yang J; Xu Y; Jiang J; Chen L; Jiang J; Wang N
    PLoS One; 2016; 11(2):e0148915. PubMed ID: 26900702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of injecting drug use on response to highly active antiretroviral treatment in HIV-1-infected patients: a nationwide population-based cohort study.
    Larsen MV; Omland LH; Gerstoft J; Røge BT; Larsen CS; Pedersen G; Obel N; Kronborg G
    Scand J Infect Dis; 2010 Dec; 42(11-12):917-23. PubMed ID: 20840000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Body Composition and Other Clinical Factors with Incomplete Immune Response after Highly Active Antiretroviral Therapy.
    Sun PT; Yu W; Li TS; Lin Q; Guo FP; Zhou XH; Du GY; Xu Y; Guan WM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):459-464. PubMed ID: 28877821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sub-optimal CD4 recovery on long-term suppressive highly active antiretroviral therapy is associated with favourable outcome.
    Onen NF; Overton ET; Presti R; Blair C; Powderly WG; Mondy K
    HIV Med; 2009 Aug; 10(7):439-46. PubMed ID: 19459993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incomplete Recovery of CD4 Cell Count, CD4 Percentage, and CD4/CD8 Ratio in Patients With Human Immunodeficiency Virus Infection and Suppressed Viremia During Long-term Antiretroviral Therapy.
    Mutoh Y; Nishijima T; Inaba Y; Tanaka N; Kikuchi Y; Gatanaga H; Oka S
    Clin Infect Dis; 2018 Aug; 67(6):927-933. PubMed ID: 29509894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of 5-year mortality in HIV-infected adults starting highly active antiretroviral therapy in Thailand.
    Fregonese F; Collins IJ; Jourdain G; Lecoeur S; Cressey TR; Ngo-Giang-Houng N; Banchongkit S; Chutanunta A; Techapornroong M; Lallemant M;
    J Acquir Immune Defic Syndr; 2012 May; 60(1):91-8. PubMed ID: 22293548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy.
    Puthanakit T; Kerr S; Ananworanich J; Bunupuradah T; Boonrak P; Sirisanthana V
    Pediatr Infect Dis J; 2009 Jun; 28(6):488-92. PubMed ID: 19504731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort.
    van Lelyveld SF; Gras L; Kesselring A; Zhang S; De Wolf F; Wensing AM; Hoepelman AI;
    AIDS; 2012 Feb; 26(4):465-74. PubMed ID: 22112603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with immunological non-response after ART initiation: a retrospective observational cohort study.
    Zhao H; Feng A; Luo D; Yuan T; Lin YF; Ling X; Zhong H; Li J; Li L; Zou H
    BMC Infect Dis; 2024 Jan; 24(1):138. PubMed ID: 38287246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated dendritic cells and monocytes in HIV immunological nonresponders: HIV-induced interferon-inducible protein-10 correlates with low future CD4+ recovery.
    Stiksrud B; Aass HCD; Lorvik KB; Ueland T; Trøseid M; Dyrhol-Riise AM
    AIDS; 2019 Jun; 33(7):1117-1129. PubMed ID: 30789356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+ cells recovery in HIV positive patients with severe immunosuppression at HAART initiation at Centre Medico-Social Cor-Unum, Kigali.
    Merci NM; Emerence U; Augustin N; Habtu M; Julie I; Angelique T; Jessica B; Cynthia A; Penda AT
    Pan Afr Med J; 2017; 26():14. PubMed ID: 28450993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters.
    Waters L; Fisher M; Anderson J; Wood C; Delpech V; Hill T; Walsh J; Orkin C; Bansi L; Gompels M; Phillips A; Johnson M; Gilson R; Easterbrook P; Leen C; Porter K; Gazzard B; Sabin C;
    HIV Med; 2011 May; 12(5):289-98. PubMed ID: 21054749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.
    Hunt PW; Deeks SG; Rodriguez B; Valdez H; Shade SB; Abrams DI; Kitahata MM; Krone M; Neilands TB; Brand RJ; Lederman MM; Martin JN
    AIDS; 2003 Sep; 17(13):1907-15. PubMed ID: 12960823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study.
    Florence E; Lundgren J; Dreezen C; Fisher M; Kirk O; Blaxhult A; Panos G; Katlama C; Vella S; Phillips A;
    HIV Med; 2003 Jul; 4(3):255-62. PubMed ID: 12859325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of earlier HAART initiation on the immune status and clinical course of treated patients on the basis of cohort data of the German Competence Network for HIV/AIDS.
    Plettenberg A; Brockmeyer NH; Haastert B; Michalik C; Dupke S; Schewe K; Rausch M; Hower M; Ulmer A; Wolf E; Lorenzen T; Arendt G; Jansen K;
    Infection; 2011 Feb; 39(1):3-12. PubMed ID: 21221704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.